Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring#China#Shanghai#Mabwell#Anti-IL-11#Pathological_Scarring
Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring
Mabwell marks a milestone with the first dosing in China of its innovative anti-IL-11 antibody, aiming to treat pathological scarring in a Phase II trial.
third-news.com
December 30, 2025 at 2:12 PM
Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring#China#Shanghai#Mabwell#Anti-IL-11#Pathological_Scarring